The renin-angiotensin-aldosterone system (RAAS) plays a major role in blood pressure regulation, and is thus an important therapeutic target in the management of hypertension. Angiotensin receptor blockers (ARBs), which interrupt RAAS overactivity by blocking a specific receptor of angiotensin Ⅱ, act for the management of hypertension. Clinical evidence demonstrates that ARBs are effective in the management of hypertension as monotherapy or in combination with other agents. Although comparable to angiotensin-converting enzyme inhibitors and other major classes of antihypertensive agents in the treatment of hypertension, ARBs are attractive alternatives for many patients due to its favorable tolerability profile. Recent evidence suggests that treatment persistence with ARBs therapy during a 12-month period be typically higher than that with other antihypertensive classes, and fewer side effects are observed. The advantages of clinical efficacy and tolerability qualify the ARBs as major treatment alternatives for hypertension.